Infections in Systemic Lupus Erythematosus

Area of Science:

• Rheumatology
• Infectious Diseases
• Clinical Medicine

Background:

• Infections represent a significant cause of morbidity and mortality in patients with Systemic Lupus Erythematosus (SLE).
• Understanding the spectrum and outcomes of infections in SLE is crucial for patient management.

Purpose of the Study:

• To determine the spectrum of infections in SLE patients.
• To correlate disease parameters with infection severity and outcomes.
• To compare infection outcomes across different immunosuppressive therapies.

Main Methods:

• A cross-sectional study included 104 SLE patients (aged ≥12 years) who developed infections over 18 months.
• Exclusion criteria: immunocompromised status due to coexisting diseases (diabetes, HIV, cancer).
• 139 infection episodes were analyzed, with data on disease parameters, treatment, and outcomes.

Main Results:

• Bacterial infections (44%) were most common, followed by fungal (16%), viral (14%), and parasitic (3%). Tuberculosis was the most frequent infection (28.78%), often extrapulmonary.
• Lower respiratory tract infections were most common (26.62%). High SLE Disease Activity Index (SLEDAI ≥5) and end-organ damage (82.7%) were prevalent.
• Central nervous system infections were more frequent with Cyclophosphamide use (p=0.01). Five deaths occurred, associated with high-dose prednisolone or cytotoxic drugs.

Conclusions:

• SLE patients are susceptible to a wide range of infections, from minor to life-threatening.
• Preventive strategies, including screening and minimizing immunosuppression while controlling disease activity, are essential.
• While treatment modality showed no association with infection severity, careful monitoring of patients on high-dose immunosuppressants is warranted.